New Vaccine Shows Promise Against Pancreatic Cancer

Early clinical and preclinical results are showing that an experimental mRNA and nanoparticle vaccine produced measurable immune responses against pancreatic cancer, and that in small patient groups, those immune responses correlated with delayed recurrence or prolonged survival.

Personalized Melanoma Vaccine Elicits Strong Immune Response

Results of a Dana-Farber Cancer Institute-initiated Phase I clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine called NeoVaxMI is safe, feasible and improves the vaccine-specific immune response compared to previous trials of the platform.

Activating B Cells Key to TIL Cancer Therapy Effectiveness

Researchers at Moffitt Cancer Center have found that tapping into the body’s own immune system and activating a type of immune cell known as B cells could be the key to boosting the effectiveness of tumor-infiltrating lymphocyte, or TIL therapy.

Nasal Spray Blocks Infuenza in Mice

Scientists at Ohio State University have created an antibody that was successful in protecting a majority of the tested mice from lethal influenza (flu) doses, even preventing some from experiencing any symptoms at all.

New Antibiotic Enters Phase III Trials to Fight Superburg

Roche’s novel antibiotic zosurabalpin is  entering Phase III testing to determine its effectiveness in protecting against carbapenem-resistant Acinetobacter baumannii (CRAB), am antimicrobial resistance (AMR) drug, or “superbug,” that is considered an “urgent threat” by the Centers for Disease Control and Prevention (CDC).